Summary of Key Information:
Nature of Filing / Announcement: Outcome of Board Meeting - Closure of Subsidiary
Date of Board Meeting / Approval: November 05, 2026
Key Financial Highlights [Unit: GBP (£)]
Subsidiary Financials (F.Y. 2025-26):
- Turnover: Nil
- Loss: £1,260
- Net Assets: £30,231 (mostly comprising cash at bank)
Corporate Actions:
The Board of Directors has approved the closure of the Company's wholly-owned subsidiary, Fermenta Biotech (UK) Limited (FBL UK), by way of feasible permissible modes as per the provisions of United Kingdom Law.
Annexure A Disclosures (SEBI LODR Regulation 30):
- Turnover/revenue/income contributed in last financial year: Nil
- Date of agreement for sale: Not Applicable
- Expected completion date: Cannot be ascertained; timelines shall be as per statutory provisions and procedures.
- Consideration: Not Applicable (closure, not sale)
- Buyer details: Not Applicable
- Related party transaction: Not Applicable
- Sale outside Scheme of Arrangement: Not Applicable
Other Significant Information:
The formal disclosure is made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.
The letter was signed by Varadvinayak Khambete, Company Secretary & Head - Legal (Membership No. A33861).